Drug Profile
Insulin inhalation - Aerogen
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Aerogen; Nektar Therapeutics
- Developer Aerogen
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 01 Feb 2017 Discontinued - Phase-II for Diabetes mellitus in Europe (PO)
- 01 Feb 2017 Discontinued - Phase-II for Diabetes mellitus in USA (PO)
- 13 Feb 2003 Suspended - Phase-II for Diabetes mellitus in Europe (PO)